Hypomagnesemia and survival in patients with head and neck cancers who received primary concurrent chemoradiation.
Adolescent
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Cancer Survivors
Carboplatin
/ administration & dosage
Chemoradiotherapy
/ adverse effects
Cisplatin
/ administration & dosage
Female
Head and Neck Neoplasms
/ complications
Humans
Magnesium Deficiency
/ chemically induced
Male
Middle Aged
Paclitaxel
/ administration & dosage
Prognosis
carboplatin
cisplatin
head and neck cancer
hypomagnesemia
radiotherapy
survival
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
15 02 2021
15 02 2021
Historique:
received:
02
07
2020
revised:
24
08
2020
accepted:
07
09
2020
pubmed:
22
10
2020
medline:
23
9
2021
entrez:
21
10
2020
Statut:
ppublish
Résumé
Prior research has confirmed that persistent hypomagnesemia was predictive of shorter survival among patients with ovarian cancer who received carboplatin-based chemotherapy. In the current retrospective study, the authors examined the association between hypomagnesemia and survival in patients with head and neck cancer who received concurrent chemoradiation with weekly infusions of cisplatin and/or carboplatin. Patients with head and neck cancers who had undergone chemoradiation with cisplatin and/or carboplatin between January 1, 2010, and December 31, 2014, were included. Patients were aged ≥18 years with pathology of squamous cell carcinoma of the larynx, oral cavity, or oropharynx who had received at least 30 fractions of radiotherapy with concurrent weekly cisplatin and/or carboplatin. Pathology features, laboratory results, Eastern Cooperative Oncology Group performance status, social histories, and survival were recorded. The association between hypomagnesemia and survival was analyzed controlling for known prognostic factors. The final cohort consisted of 439 patients with a median age of 59 years. A greater frequency of hypomagnesemia during the treatment course was found to be significantly associated with shorter survival (hazard ratio [HR], 1.13; P = .033) independent of age (HR, 1.65; P = .042), cancer site (nonoropharynx vs oropharynx: HR, 2.15 [P = .003]), Eastern Cooperative Oncology Group performance status (>1 vs ≤1: HR, 2.64 [P < .001]), and smoking history (smoker vs nonsmoker: HR, 1.88 [P = .012]). In addition, more severe hypomagnesemia was associated with shorter survival compared with the milder form. The frequency and severity of hypomagnesemia during treatment are prognostic of survival for patients with head and neck cancers who are receiving concurrent chemoradiation with cisplatin and/or carboplatin. A prospective study is needed to investigate the impact of the prevention of hypomagnesemia on survival in this patient population.
Sections du résumé
BACKGROUND
Prior research has confirmed that persistent hypomagnesemia was predictive of shorter survival among patients with ovarian cancer who received carboplatin-based chemotherapy. In the current retrospective study, the authors examined the association between hypomagnesemia and survival in patients with head and neck cancer who received concurrent chemoradiation with weekly infusions of cisplatin and/or carboplatin.
METHODS
Patients with head and neck cancers who had undergone chemoradiation with cisplatin and/or carboplatin between January 1, 2010, and December 31, 2014, were included. Patients were aged ≥18 years with pathology of squamous cell carcinoma of the larynx, oral cavity, or oropharynx who had received at least 30 fractions of radiotherapy with concurrent weekly cisplatin and/or carboplatin. Pathology features, laboratory results, Eastern Cooperative Oncology Group performance status, social histories, and survival were recorded. The association between hypomagnesemia and survival was analyzed controlling for known prognostic factors.
RESULTS
The final cohort consisted of 439 patients with a median age of 59 years. A greater frequency of hypomagnesemia during the treatment course was found to be significantly associated with shorter survival (hazard ratio [HR], 1.13; P = .033) independent of age (HR, 1.65; P = .042), cancer site (nonoropharynx vs oropharynx: HR, 2.15 [P = .003]), Eastern Cooperative Oncology Group performance status (>1 vs ≤1: HR, 2.64 [P < .001]), and smoking history (smoker vs nonsmoker: HR, 1.88 [P = .012]). In addition, more severe hypomagnesemia was associated with shorter survival compared with the milder form.
CONCLUSIONS
The frequency and severity of hypomagnesemia during treatment are prognostic of survival for patients with head and neck cancers who are receiving concurrent chemoradiation with cisplatin and/or carboplatin. A prospective study is needed to investigate the impact of the prevention of hypomagnesemia on survival in this patient population.
Identifiants
pubmed: 33085092
doi: 10.1002/cncr.33283
pmc: PMC8884478
mid: NIHMS1780456
doi:
Substances chimiques
Carboplatin
BG3F62OND5
Paclitaxel
P88XT4IS4D
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
528-534Subventions
Organisme : NCI NIH HHS
ID : K07 CA201013
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NIH HHS
ID : P30 CA016672
Pays : United States
Informations de copyright
© 2020 American Cancer Society.
Références
Eur J Cancer. 2009 Dec;45(18):3213-9
pubmed: 19850470
Diabetes Care. 2012 Jul;35(7):1591-7
pubmed: 22498805
Pediatr Blood Cancer. 2007 Feb;48(2):140-7
pubmed: 16724313
Nutrients. 2017 Mar 17;9(3):
pubmed: 28304338
J Clin Hypertens (Greenwich). 2011 Nov;13(11):843-7
pubmed: 22051430
Sci Rep. 2018 Feb 1;8(1):2047
pubmed: 29391418
J Clin Invest. 2007 Aug;117(8):2086-9
pubmed: 17671646
JAMA. 2011 Oct 12;306(14):1549-56
pubmed: 21990298
Clin Oncol (R Coll Radiol). 2006 Nov;18(9):710-8
pubmed: 17100159
Cancer Treat Rev. 1999 Feb;25(1):47-58
pubmed: 10212589
Mayo Clin Proc. 2016 Mar;91(3):386-96
pubmed: 26944243
Oncologist. 2019 Jun;24(6):e312-e317
pubmed: 30940743
Clin Cancer Res. 2008 Jul 1;14(13):4219-24
pubmed: 18594003
Clin Colorectal Cancer. 2016 Sep;15(3):e117-23
pubmed: 26961757
Cancer Chemother Pharmacol. 2005 Nov;56(5):535-42
pubmed: 15947931
JAMA Oncol. 2017 Feb 1;3(2):169-177
pubmed: 27930766
Eur J Pharmacol. 2017 Sep 15;811:191-198
pubmed: 28529140
Lancet Oncol. 2007 May;8(5):387-94
pubmed: 17466895
Int J Cancer. 2018 Jul 1;143(1):32-44
pubmed: 29405297
Head Neck. 2007 Aug;29(8):779-92
pubmed: 17230556
Am J Physiol Renal Physiol. 2017 Aug 1;313(2):F339-F350
pubmed: 28424213